Join us October 22-25 at the Orange County Convention Center, Orlando FL for the world's premier gathering of pharmaceutical scientists.
Featured Presentation
Integrated Bioanalysis and Biotransformation Strategies for Antibody-Drug Conjugates
Li Qu, Ph.D. | Deputy Director, Non-GLP Bioanalysis, WuXi AppTec
Peng Li, Ph.D. | Senior Scientist, MetID, WuXi AppTec
This presentation will explore the comprehensive evaluation of Antibody-Drug Conjugates (ADCs) through integrated bioanalysis and advanced biotransformation studies. Key topics include nonclinical pharmacokinetic assessment, metabolite profiling, Drug-to-Antibody Ratio (DAR) analysis, and strategies to address ADC complexities throughout development. Attendees will gain insights into leveraging multiple analytical platforms and hybrid methods to overcome challenges in ADC drug development, facilitating the ADC drug R&D process.
Learning Objectives:
Understand the role of integrated bioanalysis in nonclinical pharmacokinetic evaluation of ADCs.
Learn advanced methodologies for ADC biotransformation, including metabolite profiling and DAR analysis.
Explore strategies to overcome challenges in ADC development using comprehensive analytical approaches.
Posters
Other Resources
-
Posters
-
Other Resources
-
-
Comparative Metabolite Profiling and Identification of a GalNAc-Conjugated siRNA, siRNA01, in Plasma Prepared with Various Anticoagulants, Serum, and In Vivo Plasma Using LC-UV-HRMS
This research uses minipigs, chosen for their skin’s similarity to human skin, as a focus of our study. This poster evaluates the bead milling and traditional homogenization methods for processing pig skin tissues, with an emphasis on efficiency and cross-contamination prevention. We highlight the importance of accurate skin layer separation and uniform, high-quality homogenization samples for successful biological analysis. The detailed process of isolating various skin layers underscores the crucial role of homogenization in ensuring accurate results.Hepatocytes are recommended as a good in vitro metabolism model for oligonucleotides because they closely mimic the uptake into specific compartments of hepatocytes in vivo. However, there are some challenges in using hepatocytes to study the metabolism of GalNAc-conjugated siRNAs compared to that of conventional small molecules. In this study, we selected siRNA01, a commercially available GalNAc-conjugated siRNA, as a model compound for a comprehensive investigation into both in vitro and in vivo metabolism. A detailed comparison of in vivo and in vitro metabolite profiles in rats was conducted.
View More -
-
-
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads and Their DMPK Considerations
ArticlesDec 10,2024 -
Spotlight on the DMPK and Bioanalysis Strategy of Antibody Oligonucleotide Conjugates (AOCs)
ArticlesNov 21,2024 -
In Vitro Metabolic Stability Evaluation of ADCs in Plasma and Whole Blood
PostersOct 17,2024
-
Related Services and Platforms
-
MetID (Metabolite Profiling and Identification)Learn More
-
Novel Drug Modalities DMPK Enabling PlatformsLearn More
-
In Vitro MetID (Metabolite Profiling and Identification)Learn More
-
In Vivo MetID (Metabolite Profiling and Identification)Learn More
-
Metabolite Biosynthesis and Structural CharacterizationLearn More
-
Metabolites in Safety Testing (MIST)Learn More
-
PROTAC DMPK ServicesLearn More
-
ADC DMPK ServicesLearn More
-
Oligo DMPK ServicesLearn More
-
PDC DMPK ServicesLearn More
-
Peptide DMPK ServicesLearn More
-
mRNA DMPK ServicesLearn More
-
Covalent Drugs DMPK ServicesLearn More
Stay Connected
Keep up with the latest news and insights.